Literature DB >> 19520609

Activity of DSA against anaerobically adapted Mycobacterium bovis BCG in vitro.

Nicole M Parrish1, Chiew G Ko, James D Dick.   

Abstract

DSA is a beta-sulfonylacetamide with in vitro activity against pathogenic mycobacteria. Although the enzymatic target(s) of DSA has not been identified, studies to date suggest that this class of compounds may interfere directly or indirectly with ATP synthase and other components of the mycobacterial respiratory chain. In this study we further evaluated the in vitro activity of DSA against anaerobically adapted BCG using two established models. DSA killed BCG in the anaerobic Wayne model. Bactericidal activity ranged from >99% to 60%. DSA killed rifampin-tolerant persisters with a reduction in viable counts of 1.5log(10) versus controls. Conclusive identification of the DSA-specific target(s) will permit a better understanding of the unique mechanism of action of this class of compounds against both aerobically growing and anaerobically adapted bacilli in vitro.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19520609      PMCID: PMC2760961          DOI: 10.1016/j.tube.2009.05.002

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  6 in total

1.  Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis.

Authors:  Yanmin Hu; Anthony R M Coates; Denis A Mitchison
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

2.  An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence.

Authors:  L G Wayne; L G Hayes
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

3.  Oxygen depletion-induced dormancy in Mycobacterium bovis BCG.

Authors:  A Lim; M Eleuterio; B Hutter; B Murugasu-Oei; T Dick
Journal:  J Bacteriol       Date:  1999-04       Impact factor: 3.490

4.  In vitro activity of a novel antimycobacterial compound, N-octanesulfonylacetamide, and its effects on lipid and mycolic acid synthesis.

Authors:  N M Parrish; T Houston; P B Jones; C Townsend; J D Dick
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

5.  A new class of antituberculosis agents.

Authors:  P B Jones; N M Parrish; T A Houston; A Stapon; N P Bansal; J D Dick; C A Townsend
Journal:  J Med Chem       Date:  2000-08-24       Impact factor: 7.446

6.  Effect of n-octanesulphonylacetamide (OSA) on ATP and protein expression in Mycobacterium bovis BCG.

Authors:  Nicole M Parrish; Chiew G Ko; Minerva A Hughes; Craig A Townsend; James D Dick
Journal:  J Antimicrob Chemother       Date:  2004-09-08       Impact factor: 5.790

  6 in total
  3 in total

Review 1.  Energy metabolism and drug efflux in Mycobacterium tuberculosis.

Authors:  Philippa A Black; Robin M Warren; Gail E Louw; Paul D van Helden; Thomas C Victor; Bavesh D Kana
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

Review 2.  Targeting Phenotypically Tolerant Mycobacterium tuberculosis.

Authors:  Ben Gold; Carl Nathan
Journal:  Microbiol Spectr       Date:  2017-01

3.  Anaerobic adaptation of Mycobacterium avium subspecies paratuberculosis in vitro: similarities to M. tuberculosis and differential susceptibility to antibiotics.

Authors:  Nicole Parrish; Aravinda Vadlamudi; Neil Goldberg
Journal:  Gut Pathog       Date:  2017-06-10       Impact factor: 4.181

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.